> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Summit Considering Additional Ridinilazole Trial
- URL: https://www.fdaweb.com/summit-considering-additional-ridinilazole-trial/
- Published: 2022-07-14T12:00:00.000Z
- Updated: 2026-09-14T17:51:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152277

Summit Therapeutics says it will consider at least one additional clinical trial (XXX SINGULAR XXX) of its ridinilazole, an investigational treatment for *C. Diff* infection, as discussed at a recent Type C meeting with FDA officials. The company says the meeting focused on data from the Ri-CoDiFy Phase 3 trial and a discussion of a possible pathway for moving ridinilazole toward marketing authorization.